MDWD
NASDAQMediWound Ltd.
News · 26 weeks16-75%
2026-04-192026-10-11
Mix890d
- Other3(38%)
- Earnings2(25%)
- Insider2(25%)
- SEC Filings1(13%)
Latest news
25 items- PRMediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care YAVNE, Israel, September 22, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid® as a non-surgical debridement solution for battlefield burn
- PRIndependent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without ModificationIndependent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx® in patients with venous leg ulcers (VLU). Following its review
- INSIDERDirector Rubinstein Samuel sold $6,678 worth of Ordinary Shares (525 units at $12.72) and bought $6,626 worth of Ordinary Shares (525 units at $12.62) (SEC Form 4)4 - MediWound Ltd. (0001593984) (Issuer)
- PRMediWound to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceMediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. The fireside chat, moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright, is scheduled for Monday, September 14, 2026, at 2:00 p.m. ET. A live webcast of
- INSIDERCOO & Chief Commercial Officer Hess Shmuel sold $75,394 worth of Ordinary Shares (5,823 units at $12.95), closing all direct ownership in the company (SEC Form 4)4 - MediWound Ltd. (0001593984) (Issuer)
- SECSEC Form 6-K filed by MediWound Ltd.6-K - MediWound Ltd. (0001593984) (Filer)
- PRMediWound Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateEscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "In the second quarter, we continued to make meaningful progress w
- PRMediWound to Report Second Quarter 2026 Financial ResultsMediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. On the same day, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call & Webcast Details Toll-Free: 1-844-676-8833Israel:
- INSIDERDirector Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)4 - MediWound Ltd. (0001593984) (Issuer)
- INSIDERDirector Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)4 - MediWound Ltd. (0001593984) (Issuer)
- INSIDERDirector Rubinstein Samuel bought $2,150 worth of Ordinary Shares (150 units at $14.33), increasing direct ownership by 5% to 2,993 units (SEC Form 4)4 - MediWound Ltd. (0001593984) (Issuer)
- SECSEC Form 6-K filed by MediWound Ltd.6-K - MediWound Ltd. (0001593984) (Filer)
- PRMediWound Reports First Quarter 2026 Financial Results and Provides Corporate UpdateEscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. "During the first quarter, we continued to advance both our strategic and operational priorities," said Ofer Gonen, Chief Execut
- SECSEC Form SCHEDULE 13G filed by MediWound Ltd.SCHEDULE 13G - MediWound Ltd. (0001593984) (Subject)
- PRMediWound to Report First Quarter 2026 Financial ResultsMediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the first quarter ended March 31, 2026 on Wednesday, May 27, 2026. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call & Webcast Details Toll-Free: 1-844-676-8833Israel:
- SECSEC Form 6-K filed by MediWound Ltd.6-K - MediWound Ltd. (0001593984) (Filer)
- PRNewly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound DebridementNewly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx® in chronic wound care YAVNE, Israel, April 13, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today highlighted the publication of a peer-reviewed supplement in WOUNDS titled "Toward a Practical Framework for Debridement in Chronic Wounds: Findings From
- PRMediWound to Present New EscharEx® Data at Leading Wound Care ConferencesMediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel, April 7, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced multiple oral and poster presentations at three leading wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2026, taking place April 8–12 in Charlotte, North Carolina, and the European Wou
- SECSEC Form 6-K filed by MediWound Ltd.6-K - MediWound Ltd. (0001593984) (Filer)
- PRMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Vericel reported that the contract is for the procureme
- SECSEC Form 6-K filed by MediWound Ltd.6-K - MediWound Ltd. (0001593984) (Filer)
- INSIDERSEC Form 3 filed by new insider Driver Vickie Rae3 - MediWound Ltd. (0001593984) (Issuer)
- INSIDERSEC Form 3 filed by new insider Klinger Ety3 - MediWound Ltd. (0001593984) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fox David Morton3 - MediWound Ltd. (0001593984) (Issuer)
- INSIDERSEC Form 3 filed by new insider Luxenburg Kalfon Hana3 - MediWound Ltd. (0001593984) (Issuer)
MDWD FAQ
7 questionsWhat does MediWound Ltd. do?
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial...Where does MDWD stock trade?
MediWound Ltd. (MDWD) is listed on NASDAQ.What sector and industry is MDWD in?
MediWound Ltd. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did MediWound Ltd. go public?
MediWound Ltd. (MDWD) completed its IPO in 2014.What are analysts saying about MDWD?
MediWound Ltd. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $3400.00 price target on 2025-06-02.What companies are similar to MDWD?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), DFTX (Definium Therapeutics Inc.). Compare MDWD side-by-side with any of them on Quantisnow.How can I track MDWD on Quantisnow?
Quantisnow aggregates MediWound Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDWD to receive live email and push alerts on every new disclosure.